Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lung Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm
Lung Neoplasm

Cancer Family

Lung Neoplasm

CI-CAN-00000221Explore in graph →

Non-malignant2,726 active trials51 approved drugs619 evidence items

NCIt: C3200
MeSH: D008175

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11603
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
· Oncologist · 2014 · PMID 24868098 · validated civic_curation pubmed
Afatinib: first global approval.
· Drugs · 2013 · PMID 23982599 · validated civic_curation pubmed
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
· JAMA · 2017 · PMID 28492898 · validated civic_curation pubmed
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
· Ann Oncol · 2019 · PMID 30980071 · validated civic_curation pubmed
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
· N Engl J Med · 2017 · PMID 28586279 · validated civic_curation pubmed
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
· Lancet Oncol · 2017 · PMID 28602779 · validated civic_curation pubmed
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Showing 101–125 of 483 publications

← Previous
1
…
4
5
6
…
20
Next →

· Lancet · 2017 · PMID 28501140 · validated civic_curation pubmed

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

· N Engl J Med · 2021 · PMID 34096690 · validated civic_curation pubmed

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

· J Clin Oncol · 2020 · PMID 32780660 · validated civic_curation pubmed

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

· Lancet Oncol · 2020 · PMID 31838015 · validated civic_curation pubmed

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

· N Engl J Med · 2020 · PMID 32955177 · validated civic_curation pubmed

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28958502 · validated civic_curation pubmed

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

· Lancet Oncol · 2019 · PMID 31591063 · validated civic_curation pubmed

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

· N Engl J Med · 2024 · PMID 38598794 · validated civic_curation pubmed

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

· N Engl J Med · 2023 · PMID 37937763 · validated civic_curation pubmed

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

· N Engl J Med · 2014 · PMID 25264305 · validated civic_curation pubmed

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

· Lancet Oncol · 2016 · PMID 27283860 · validated civic_curation pubmed

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

· J Clin Oncol · 2018 · PMID 29596029 · validated civic_curation pubmed

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

· J Clin Oncol · 2021 · PMID 34339292 · validated civic_curation pubmed

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

· JAMA Oncol · 2021 · PMID 34647988 · validated civic_curation pubmed

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

· Lancet Oncol · 2021 · PMID 34118197 · validated civic_curation pubmed

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

· Br J Cancer · 2014 · PMID 24263064 · validated civic_curation pubmed

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.

· J Clin Oncol · 2023 · PMID 37694347 · validated civic_curation pubmed

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

· N Engl J Med · 2023 · PMID 37870976 · validated civic_curation pubmed